* Iveric Bio Inc ISEE.OQ ISEE.O is expected to show a no
change in quarterly revenue when it reports results on August
4.
* Refinitiv's mean analyst estimate for Iveric Bio Inc is for a
loss of 26 cents per share. For the same quarter last year, the
company reported a loss of 32 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Iveric Bio Inc
is $15, about 42.5% above its last closing price of $8.63.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.25 -0.25 -0.29 Missed -16.5
Dec. 31 2020 -0.26 -0.27 Missed -5.5
Sep. 30 2020 -0.22 -0.22 -0.27 Missed -23.6
Jun. 30 2020 -0.31 -0.31 -0.32 Missed -3.2
Mar. -0.39 -0.39 -0.28 Beat 28.2
31 2020
Dec. 31 2019 -0.28 -0.28 -0.39 Missed -39.3
This summary was machine generated August 2 at 12:31 GMT. All
figures in US dollars unless otherwise stated